Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Zika virus envelope (E) glycoprotein is the primary surface protein of the Zika virus (ZIKV) and a critical mediator of viral entry and pathogenesis. It is a class II viral fusion protein organized as a homodimer on the mature virion surface, consisting of three distinct ectodomains (DI, DII, and DIII) and a transmembrane anchor. The E protein facilitates the initial attachment of the virus to host cell receptors, such as DC-SIGN and GRP78, and mediates membrane fusion within the acidic environment of the endosome to release the viral genome into the cytoplasm. As the dominant target of the host's neutralizing humoral immune response, the E protein is the focal point for vaccine development and monoclonal antibody (mAb) therapies. Key epitopes, such as the fusion loop in DII and the lateral ridge in DIII, are targeted by potent neutralizing antibodies like ZIKV-117. However, a significant therapeutic challenge is antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies from prior flavivirus infections can facilitate viral entry into Fc-receptor-bearing cells, potentially exacerbating disease. Consequently, drug and vaccine design must prioritize the induction of highly specific, strongly neutralizing antibodies to avoid these safety risks.
Neutralization of viral particles by blocking receptor binding sites, inhibition of pH-dependent conformational changes required for membrane fusion, and prevention of viral entry into host cells.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zika virus envelope glycoprotein (ZIKV E protein).